Drug intelligence / Profile preview

LXH254 + ribociclib

Development stage: Unknown
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral

Overview

This combination involves LXH254, a potent and selective adenosine triphosphate (ATP)-competitive inhibitor of the BRAF and CRAF protein kinases, and ribociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. The combination is being studied for its efficacy in treating previously treated unresectable or metastatic melanoma, particularly in patients with BRAFV600 or NRAS mutant melanoma.

Targets

CDK6 (Cyclin-dependent kinase 6)RAF1 (c-Raf-1 (Y340D/Y341D))CDK4 (Cyclin-dependent kinase 4)BRAF (B-Raf proto-oncogene, serine/threonine kinase)

Beyond the preview

Go deeper on LXH254 + ribociclib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LXH254 + ribociclib.

Explore the full profile